XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $271K invested in XTL Biopharmaceuticals in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
60% less capital invested
Capital invested by funds: $678K → $271K (-$407K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $221K | – | – | – |
|
|
2
Morgan Stanley
New York
| $50K | -$5.43K | -875 | -7% |
|
|
NC
3
Noked Capital
Tel Aviv,
Israel
| $221 | – | – | – |
|
XTLB Hedge Fund Activity: Q3 2022 in Review
3 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2022, worth a combined $271K — down 60% from $678K a quarter earlier.
Fund positioning in XTLB was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Morgan Stanley, cutting an estimated $5.43K.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $271K of XTL Biopharmaceuticals stock for Q3 2022, down 60% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q3 2022 and 0 closed out.
- The largest XTL Biopharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $5.43K sold.
Based on aggregated 13F filings for Q3 2022.